TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics.

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...

Chief Operating Officer Ryan Fukushima recently sold a significant portion of his holdings in the company, according to a ...

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was the recipient of some unusual options trading on Wednesday. Investors bought 51,813 call options on the company. This is an increase of approximately ...

Nvidia (NASDAQ: NVDA) has been the premier AI stock in the past two years. It now has a market cap in the trillions. Nancy Pelosi has seen it coming for a long time. She bought the stock several times ...

Tempus AI, known for its AI-driven precision medicine,... Tuesday - Analysts at TD Cowen have initiated coverage on Tempus AI Inc (NASDAQ:TEM) stock with a Buy rating and have set a price target ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

READ NOW: 10 AI Stocks Making Waves on Wall Street and ... On January 21, Bryan Bergin from TD Cowen maintained a Hold rating on UiPath with a price target of $16.00. Several factors associated ...